BURSTNature, Published online: 22 April 2026; doi:10.1038/s41586-026-10436-4
The Lap-NET1 phase 1b trial reports that combined netrin1 antibody (NP137) plus modified FOLFIRINOX therapy on patients with locally advanced pancreatic cancer was well tolerated and improved progression-free survival and overall survival via inhibition of epithelial–mesenchymal transition.